Renalytix Plc (RNLXY)
| Market Cap | 25.39M -24.0% |
| Revenue (ttm) | 3.30M +40.3% |
| Net Income | -19.90M |
| EPS | -0.05 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189 |
| Open | 3.000 |
| Previous Close | 3.250 |
| Day's Range | 3.000 - 3.000 |
| 52-Week Range | 0.999 - 8.090 |
| Beta | 1.81 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 28, 2026 |
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl... [Read more]
Financial Performance
In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.
Financial StatementsNews
KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists
Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and - for the fi...
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
The novel care model will integrate FDA-approved kidneyintelX.dkd™ and Carna Health's digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, signi...
Renalytix Quarterly report: H1 2026
Renalytix has published its H1 2026 quarterly earnings report on March 26, 2026.
Renalytix Earnings release: H1 2026
Renalytix released its H1 2026 earnings on February 11, 2026, summarizing the period's financial results.
Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
New results and three presentations at ASN Kidney Week underscore kidneyintelX.dkd as a precision-medicine standard for CKD NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: R...
Renalytix Annual report: Q4 2025
Renalytix has published its Q4 2025 annual report on November 4, 2025.
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15, ...
MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities. NEW YORK , July 21, 2025 /PRNewswire/ -- Renalytix Pl...
Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025
LONDON and NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management...